Our CRAd will be able to stimulate an anti-tumor immune response in the TME owing it its oncolytic properties, including inhibiting the immune checkpoint protein PD-1 from binding to its ligand, PD-L1. The gene discussed is PDCD1; the disease is neoplasm.